Biomarkers are biochemical or molecular indicators of defined states of health, disease, or response to therapy. Biomarkers are used clinically for diagnosis, prognosis, and patient management. Understanding the limitations of biomarker assays is key to appropriate test utilization and interpretation. With increases in novel treatment modalities, the need for companion biomarker assays is growing. This course will enable participants to understand pathways to the development of biomarker assays from the research bench to the clinic, as well as to interpret results, based on understanding assay performance characteristics and limitations.
- Teacher: Lauren A. McVoy
- Teacher: Joann C. Rittersbach
Conducting safe, high-quality clinical research necessitates accounting for on- and off-target drug effects and how drugs reach those targets across a diverse cohort. Principal investigators must apply crucial pharmacotherapeutic concepts when designing clinical cancer research to ensure protocols direct efforts to manage intra- and inter-patient differences in drug exposure and maximize safety.
This course explores principles of pharmacotherapy as they relate to clinical cancer research, including pharmacokinetics, pharmacodynamics, pharmacogenomics, drug interactions, and considerations in special populations. The course’s intent is to provide investigators with a practical foundation for rational incorporation of these principles into research protocols.
- Teacher: Raymond G Dematteo
- Teacher: Stephen Harnicar
- Teacher: Andrea C. Levoir
- Teacher: Dazhi Liu
- Teacher: Long T. Nguyen